Some studies report that Nrf2 expression is reduced during active disease, while others demonstrate that pharmacological activation of Nrf2, for example with Bryostatin-1, alleviates colitis in interleukin 10 (IL-10)–deficient mice, an experimental model that mimics Crohn’s disease [174,175,176]. This evidence concerns the gene IL10 and colitis.